SORRENTO THERAPEUTICS, INC. Form 8-K (Sept. 30, 2022)

Summary

Current report on Form 8-K for an event dated September 30, 2022, filed by Sorrento Therapeutics, Inc. Under Item 1.01, the report states that on September 30, 2022 the company entered into a Bridge Loan Agreement with B. Riley Commercial Capital, LLC, as lender, and borrowed $41,670,000. The company agreed to pay B. Riley Securities, Inc., an affiliate of the lender, an upfront fee equal to one percent of the principal amount. The Bridge Loan bears interest at 6% per annum and will mature on January 31, 2023, and bears interest at the rate of 15% per annum during the continuance of an Event of Default. Henry Ji signed on September 30, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): September 30, 2022

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified
in its Charter)

Delaware | 001-36150 | 33-0344842
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)

4955 Directors Place

San Diego , CA 92121

(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number,
including area code: ( 858 ) 203-4100

N/A

(Former Name, or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.0001 par value | SRNE | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry Into a Material Definitive Agreement.

On September 30, 2022,
Sorrento Therapeutics, Inc. (the “Company”) entered into a Bridge Loan Agreement (“Loan Agreement”) between the
Company, as borrower, and B. Riley Commercial Capital, LLC, as lender (the “Lender”), pursuant to which the Company borrowed
$41,670,000 from the Lender (the “Bridge Loan”).

For services rendered
in connection with originating and arranging the Bridge Loan, the Company agreed to pay to B. Riley Securities, Inc., an affiliate
of the Lender (“BRS”), an upfront fee equal to one percent of the principal amount of the Bridge Loan. The Bridge Loan bears
interest at 6% per annum and will mature on January 31, 2023. Upon the occurrence and during the continuance of an “Event of Default”
under the Loan Agreement, the Bridge Loan shall bear interest at the rate of 15% per annum.

The Lender is an affiliate
of BRS, which is a sales agent under that certain Amended and Restated Sales Agreement, dated December 3, 2021, as amended, among the
Company, Cantor Fitzgerald & Co., B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC.

The Credit Agreement
imposes certain customary affirmative and negative covenants on the Company, as well as covenants that (i) restrict the Company and
its subsidiaries from incurring any additional indebtedness or suffering any liens, subject to certain specified exceptions, (ii) restrict
the declaration of any dividends or other distributions, subject to certain specified exceptions, and (iii) restrict the Company
from engaging in certain corporate transactions or dispositions of assets, subject to certain specified exceptions. The Loan Agreement
also includes events of default that are customary for these types of loan agreements.

The foregoing summary
of the Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Loan Agreement,
a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30,
2022.

The
representations, warranties and covenants contained in the Loan Agreement were made only for purposes of such agreement and as of specific
dates, were solely for the benefit of the parties to the Loan Agreement, and may be subject to limitations agreed upon by the contracting
parties. Accordingly, the Loan Agreement is incorporated herein by reference only to provide investors with information regarding the
terms of the Loan Agreement, and not to provide investors with any other factual information regarding the Company or its business, and
should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the Securities and Exchange
Commission.

Item 2.03. Creation of a Direct Financial
Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information included under Item 1.01 of this
Current Report on Form 8-K is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit.

104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SORRENTO THERAPEUTICS, INC.
Date: September 30, 2022 | By: | /s/ Henry Ji, Ph.D.
Name: Henry Ji, Ph.D.
Title: Chairman of the Board, President and Chief Executive Officer

File and source

File

SEC_SRNE_8-K_filed2022-09-30_0001104659-22-104522.htm

Size

28,139 bytes

SHA-256

dd374ac7e57e066acd7710c1b7cc581cb27a4ab9230c5e58642de902e5f0812f

Our copy

SEC_SRNE_8-K_filed2022-09-30_0001104659-22-104522.htm

Original

www.sec.gov